[Liver transplantation for patients infected with both HIV and HCV or HIV and HBV].
Human immunodeficiency virus infection (HIV) has been considered until recently as a contraindication for liver transplantation. This was due to the poor spontaneous prognosis of HIV infection. The advent of highly active antiretroviral drugs (HAART) was a therapeutic breakthrough, and the prognosis has been dramatically improved. 30 % and 10 % of HIV infected patients are coinfected with hepatitis C virus (HCV) and with hepatitis B virus (HBV), respectively. The progression of chronic hepatitis B and C seems more rapid in coinfected patients, and a high number of patients will develop life-threatening liver cirrhosis. There are numerous potential problems raised by liver transplantation in HIV infected patients: (1) the potential risk of needlestick injury during this type of hemorrhagic surgery at high risk of bleeding; (2) the timing for liver transplantation; (3) the risk of interference between HAART and calcineurin inhibitors; (4) The risk of HBV and HCV recurrence post-transplant. Since 1999, a program of liver transplantation has been started in patients coinfected with HIV and HBV or HCV with the support of the Agence Nationale de Recherche contre le Sida et les Hépatites virales (ANRS). The first results showed that liver transplantation in HIV-HCV and HIV-HBV infected patients is feasible, achieving 2-year survival of 70 % and 100 %, respectively. There was no acceleration of HIV disease after transplantation. HBV recurrence was well prevented by the combination of anti-HBs immunoglobulins plus nucleoside and nucleotide analogues effective against HBV. The main problem is HCV recurrence, which is more rapid and more severe in HIV coinfected patients than in HCV monoinfected patients. Understanding HCV recurrence mechanisms, and preventing and treating of HCV recurrence are major future challenges.
Duclos-Vallée
Jean-Charles
JC
Département des Maladies du Foie et INSERM U785, Unité de Maladies Infectieuses, Université Paris XI, Centre Hépato-Biliaire, Hôpital Paul Brousse, 12-14, Avenue Paul Vaillant Couturier, 94804, Villejuif, France. jean-charles.duclos-vallee@pbr.aphp.fr
Teicher
Elina
E
Vittecoq
Daniel
D
Samuel
Didier
D
D002423:Cause of Death; D015658:HIV Infections / Q000150:complications* / Q000401:mortality / Q000601:surgery; D006509:Hepatitis B / Q000150:complications / Q000401:mortality / Q000601:surgery*; D006526:Hepatitis C / Q000150:complications / Q000401:mortality / Q000601:surgery*; D006801:Humans; D016031:Liver Transplantation; D018579:Patient Selection; D016019:Survival Analysis; D017741:Survivors